Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06561360 · ClinicalTrials.gov registry record · Phase 2
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
A Phase 2 study of Hairy Cell Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
- 10
- Study locations
NCT06561360 is a Phase 2 study of Hairy Cell Leukemia that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 86 participants, above the 67-participant average among 15 other Hairy Cell Leukemia trials with a reported enrollment target (28% higher). The trial reports 10 study locations across 5 states.
The verdict
NCT06561360, a Phase 2 study of Hairy Cell Leukemia, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
- 10
- Study locations
Study Summary
The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer or milder side effects. Researchers think vemurafenib and obinutuzumab (non-chemotherapy drugs) may cause fewer side effects compared with the usual approach of chemotherapy drugs. They will also compare the two approaches to see which approach is more effective at eliminating cancer cells.
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Cladribine
- DRUG Rituximab
- DRUG Vemurafenib
Study Locations (10)
New York
- Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic Cancer Center - Rochester
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2024-09-09 |
| Est. Completion | 2027-09-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06561360
The ClinicalTrials.gov registry entry for NCT06561360 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 67-participant average among 15 other Hairy Cell Leukemia trials with a reported enrollment target (28% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hairy Cell Leukemia appearing as the primary indexed condition, and to 4 interventions - of which Obinutuzumab is the first listed.
NCT06561360 reports 10 study locations spanning 5 distinct geographic areas - top geographies include New York, New Jersey, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06561360 about?
NCT06561360 is a clinical study titled "A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)". The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer or milder side effects. Researchers think vemurafenib and obin...
What is the current status of trial NCT06561360?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2024-09-09. Estimated completion is 2027-09-09.
What conditions does trial NCT06561360 study?
This clinical trial studies the following conditions: Hairy Cell Leukemia.
What interventions are being tested in trial NCT06561360?
The interventions under investigation include: Obinutuzumab (DRUG), Cladribine (DRUG), Rituximab (DRUG), Vemurafenib (DRUG).
Who is sponsoring clinical trial NCT06561360?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06561360 being conducted?
This trial has 10 study locations across Massachusetts, Minnesota, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hairy Cell Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
RECRUITING · Phase 2
-
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
RECRUITING · Phase 2
-
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
RECRUITING · Phase 2
-
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.